| MEDICIS | ||
|
Description Pure accelerated radioisotope beams have been used for 50 years for fundamental physics as illustrated more recently with the discovery of pear shape exotic nuclei in 2013; CERN-ISOLDE plays a central role in developing accelerator technologies and fostering collaborative approaches to advance this field of isotope mass separation online. Our recent contribution was the use of nanomaterials for more intense and reliable beam production and laser ion sources. Radioisotopes are widely used for functional imaging and is expected to play a major role in cancer treatment with new alpha emitters; 223Radium chloride (Xofigo®) radiopharmaceutical is now used as a treatment and pain relief drug in advanced bone cancers resistant to hormones. However, either shortage in the supply of the commonly used 99mTechnetium or lack of access to new chemical elements with adequate radioactive emission properties is a severe treat to supply these drugs or develop personalized treatment that combine functional imaging and therapy.
The CERN-MEDICIS facility is an extension of the existing class A building in which the targets to produce radioisotopes will be irradiated in the HRS dump position, behind the Isolde target, and will be brought back in CERN-MEDICIS. Radioactive ion beams will be produced on a dedicated isotope mass separator in CERN-MEDICIS to produce dedicated medical batches for radiopharmaceuticals, distributed to the medical partners of the collaboration.  |
Management
Tests & commissioning & operation |
|
